Startups
The European Hematology Association (EHA) promotes excellence in patient care, research and education in hematology.
The European Hematology Association was founded in Brussels, Belgium in June 1992, and began by organizing a biennial congress in a European city. From 1998, it became an annual event, taking place in June. Gradually, the activities of EHA expanded to cover many complementary subjects in the field of Hematology. Since its inception, EHA has broadened its activities in order to serve European hematologists in delivering state-of-the-art execution of their profession. This expansion has also had an effect on the structure and the functioning of the Association. The Board and the number of committees and units have expanded, and over the years the Executive Office have welcomed more staff members to support the work of EHA.
The European Hematology Association was founded in Brussels, Belgium in June 1992, and began by organizing a biennial congress in a European city. From 1998, it became an annual event, taking place in June. Gradually, the activities of EHA expanded to cover many complementary subjects in the field of Hematology. Since its inception, EHA has broadened its activities in order to serve European hematologists in delivering state-of-the-art execution of their profession. This expansion has also had an effect on the structure and the functioning of the Association. The Board and the number of committees and units have expanded, and over the years the Executive Office have welcomed more staff members to support the work of EHA.
Overview
Location
Netherlands, South Holland, The Hague
Employees
51-200
Phone
+31 70 302 0099
Founded date
1992
Mentions in press and media 26
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 12, 2026 | Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer | European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology lead... |
| Jan 22, 2026 | Elicera Therapeutics’ CSO invited to present at multiple scientific conferences | Elicera Therapeutics’ CSO invited to present at multiple scientific conferences Thu, Jan 22, 2026 09:43 CET Report this content Gothenburg, January 22, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company de... |
| Aug 6, 2025 | The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pret... |
| Aug 1, 2024 | Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 – – Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Pivotal AUGME... |
| Jun 18, 2024 | Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| Jun 18, 2024 | Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| Jun 17, 2024 | Kira Pharmaceuticals Presents Positive Results of KP104 Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at European Hematology Association (EHA) Congress 2024 Demonstrating Long-term Safety and Efficacy | CAMBRIDGE, Mass., June 17, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced positive long-term results from its Pha... |
| Jun 15, 2024 | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress Sat, Jun 15, 2024 17:30 CET Report this content Stockholm, June 15, 2024 - Immedica’s partner Actinium... |
| Jun 15, 2024 | CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 | SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ini... |
Show more
Reviews 0
FAQ about European Hematology Association
When was European Hematology Association founded?
European Hematology Association was founded in 1992.
What has the press written about European Hematology Association?
Parsers VC has collected 26 articles mentioning European Hematology Association, among them “Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical ...” (May 12, 2026) and “Elicera Therapeutics’ CSO invited to present at multiple scientific conferences” (Jan 22, 2026).
Is European Hematology Association still active?
Yes, European Hematology Association is active; its latest activity on Parsers VC dates from May 13, 2026.